Scott Robertson - Dice Molecules Chief Officer

Insider

Scott Robertson is Chief Officer of Dice Molecules Holdings
Phone650 566 1402
Webhttps://www.dicemolecules.com

Dice Molecules Management Efficiency

The company has return on total asset (ROA) of (0.1402) % which means that it has lost $0.1402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.216) %, meaning that it created substantial loss on money invested by shareholders. Dice Molecules' management efficiency ratios could be used to measure how well Dice Molecules manages its routine affairs as well as how well it operates its assets and liabilities.
100%
Dice Molecules Holdings currently holds 13.27 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Dice Molecules Holdings has a current ratio of 23.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Dice Molecules' use of debt, we should always consider it together with its cash and equity.
D...Cash95.51%100%

Similar Executives

Showing other executives

INSIDER Age

Siew MSAcumen Pharmaceuticals
N/A
Justin KleeAmylyx Pharmaceuticals
34
MBA MDPliant Therapeutics
56
Mike OuimettePliant Therapeutics
51
Kerry MDTerns Pharmaceuticals
N/A
Jens OkkelsAscendis Pharma AS
63
Janice HitchcockAcumen Pharmaceuticals
N/A
Gene KimDyne Therapeutics
47
David TiceArcellx
53
CMO MBAViridian Therapeutics
72
Eric MDAcumen Pharmaceuticals
69
Nuala BrennanMoonLake Immunotherapeutics
N/A
Oliver DaltropMoonLake Immunotherapeutics
N/A
Jonathan MBAViridian Therapeutics
49
Prof MDVentyx Biosciences
N/A
Jeff KnightCrinetics Pharmaceuticals
54
James HassardCrinetics Pharmaceuticals
58
Marvin CaruthersViridian Therapeutics
85
Prof ShairNuvalent
56
Mark VignolaTerns Pharmaceuticals
47
Kristian MBAViridian Therapeutics
49
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Dice Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people. Dice Molecules Holdings (DICE) is traded on NASDAQ Exchange in USA and employs 71 people.

Management Performance

Dice Molecules Holdings Leadership Team

Elected by the shareholders, the Dice Molecules' board of directors comprises two types of representatives: Dice Molecules inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dice. The board's role is to monitor Dice Molecules' management team and ensure that shareholders' interests are well served. Dice Molecules' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dice Molecules' outside directors are responsible for providing unbiased perspectives on the board's policies.
Kevin Judice, CEO Founder
Scott Robertson, Chief Officer
Timothy MD, Chief Officer
John Jacobsen, Chief Officer
Mary JD, G Counsel
Venkat Thalladi, VP CMC
Paul Fatheree, VP Chemistry

Dice Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dice Molecules a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Other Consideration for investing in Dice Stock

If you are still planning to invest in Dice Molecules Holdings check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dice Molecules' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital